2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3263 A first-in-human Phase 1 trial of miRisten, an inhibitor of microRNA-126 in adult patients with relapsed/refractory (R/R) acute myeloid leukemia (AML)

Amanda Blackmon, DO, Jianying Zhang, PhD2, Sandra Thomas, PhD3, Diana Knobler4, Brian John Ball, MD, MS5, Salman Otoukesh, MD6, Idoroenyi Amanam, MD7, Yazeed Samara, MD8, Ibrahim Aldoss, MD9, Anthony Selwyn Stein, MD10, Monzr M. M Al Malki, MD11, Karamjeet Singh Sandhu, MD12, Farrah Farshidfard, BSN13, Cindy Nguyen-Williams, MHA14, Wirlen Elame15, Bin Zhang, PhD16, Tim Synold17, Le Xuan Truong Nguyen, PhD18, Marcin Kortylewski, PhD19, Lucy Ghoda, PhD20, Guido Marcucci, MD21
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, Translational Genomics Research Institute, Phoenix, Arizona, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States

The primary cause of treatment failure in acute myeloid leukemia (AML) is disease relapse driven by persistent leukemic stem cells (LSCs) capable of indefinite self-renewal. Current therapies mainly target proliferating AML blasts and fail to eradicate LSCs, which evade killing through drug resistance and remodeling of the bone marrow (BM) microenvironment (ME) into a protective niche shielding quiescent and treatment invulnerable LSCs.

MicroRNAs (miRs) are non-coding RNAs that downregulate target messenger (m) RNAs via the RNA induced silencing complex. miR-126 functions as a master regulator of the BM ME via LSC intrinsic functions and extrinsic effects on endothelial cells (EC) influencing the BM vasculature. Elevated miR-126 levels are present in quiescent LSCs and EC lining arterioles, with lower miR-126 levels in proliferating AML blasts and in EC lining sinusoidal vessels. Arteriolar EC supply miR-126 to quiescent LSCs via exosomes. Within the LSC, miR-126 supports the stem-like phenotype and distinct mitochondrial metabolism (i.e., oxidative phosphorylation [OXPHOS]) promoting drug resistance and survival. miR-126 supports LSC dependence on OXPHOS by upregulating fatty acid oxidation (FAO) and the antioxidant response, stabilizing BCL-2 via the SPRED1/MAP kinase axis and promoting mitofusion. While both normal hematopoietic stem cells and LSCs require miR-126 for survival, LSCs exhibit a higher dependence on and vulnerability to therapeutic targeting of miR-126. In AML mouse and patient-xenograft models, treatment with standard AML therapies initially elicited a response. However, adaptive miR-126 upregulation promoted LSC survival and disease re-initiation in secondary transplant models. These findings provide a rationale for a therapeutic strategy focused on miR-126 inhibition in AML LSCs and arteriolar ECs in the BM niche.

We present a novel miR-126 inhibitor, miRisten, that targets LSCs. miRisten is a cell-selective antisense (AS) oligonucleotide inhibitor comprised of an unmethylated cytosine-phosphate-guanine (CpG) oligodeoxynucleotide that facilitates uptake of the linked AS RNA by myeloid cells and ECs via scavenger receptors and Toll-like receptor 9. Phosphorothioate and 2’-O-Me modifications provide nuclease resistance and serum stability. Mouse models demonstrated efficacy at the human equivalent dose (HED) of 1.68 mg/kg given IV (bolus) qd for 3 wks. Modeling of pharmacokinetics (PK)/pharmacodynamics (PD) in mice, rats and non-human primates (NHP) led to an optimal HED of 4.2 mg/kg bid, which suppresses miR-126 and elevates SPRED1 mRNA, a direct target of miR-126. miRisten half-life in human serum is 30’. We conducted toxicokinetic (TK) studies in rats and NHP and did not observe complement activation in NHP. Based on preclinical efficacy, PK, and TK studies, we filed an investigational new drug (IND) application with the FDA and received authorization to proceed with our clinical trial of miRisten manufactured at City of Hope.

Seven patients have been treated on this single-center, first-in-human phase 1 trial with the primary objective to assess safety and determine the recommended phase 2 dose (RP2D) of miRisten in adults with R/R AML (NCT07025564). The RP2D will be the minimum biologically effective and safe dose. The study tests 5 dose levels, starting at <0.1x the no observed adverse event level from NHP TK studies. Patients began enrolling on 0.4mg/kg IV (30’ infusion) q24h on days 1-5, 8-12 and 15-19 of one 28-day cycle. Steroid premeds are administered during week 1 to mitigate potential inflammatory reactions. Dose escalation follows a 3+3 design. Toxicity is graded by NCI-CTCAE v.5.0. Dose-limiting toxicity is defined as 1) hematologic toxicity including failure to recover neutrophil and/or platelets by day 42 from the start of the cycle in the absence of leukemia; 2) any grade ≥3 non-hematologic toxicity except specific events that resolve within 72 hours; and 3) any miRisten-related toxicity preventing administration of at least 66.7% of the agent during therapy. Secondary endpoints include miRisten PK, disease response, and survival. Exploratory endpoints include miR-126 levels, its targets (e.g., SPRED1), cytokine/complement, and BCL-2, LSC burden, and mitochondrial metabolism.

Synergy of miRisten and venetoclax (VEN) with enhanced reduction of OXPHOS and FAO in LSCs was seen preclinically. Thus, future combination trials are planned with miRisten and VEN/azacitidine for R/R AML.

Amanda Blackmon, DO: No relevant conflicts of interest to declare.